YMAB (Y-mAbs Therapeutics) FCF Margin % : -33.67% (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Y-mAbs Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Y-mAbs Therapeutics's Free Cash Flow for the three months ended in Mar. 2025 was $-7.04 Mil. Y-mAbs Therapeutics's Revenue for the three months ended in Mar. 2025 was $20.90 Mil. Therefore, Y-mAbs Therapeutics's FCF Margin % for the quarter that ended in Mar. 2025 was -33.67%.

As of today, Y-mAbs Therapeutics's current FCF Yield % is -9.87%.

The historical rank and industry rank for Y-mAbs Therapeutics's FCF Margin % or its related term are showing as below:

YMAB' s FCF Margin % Range Over the Past 10 Years
Min: -440.51 Med: -116.32 Max: -17.92
Current: -21.74

During the past 9 years, the highest FCF Margin % of Y-mAbs Therapeutics was -17.92%. The lowest was -440.51%. And the median was -116.32%.

YMAB's FCF Margin % is ranked better than
64.39% of 997 companies
in the Biotechnology industry
Industry Median: -102.06 vs YMAB: -21.74

Y-mAbs Therapeutics FCF Margin % Historical Data

The historical data trend for Y-mAbs Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-mAbs Therapeutics FCF Margin % Chart

Y-mAbs Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-440.51

-296.65

-116.32

-32.11

-17.92

Y-mAbs Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
FCF Margin %	Get a 7-Day Free Trial															-17.45	1.31	-57.77	-7.06	-33.67

Competitive Comparison of Y-mAbs Therapeutics's FCF Margin %

For the Biotechnology subindustry, Y-mAbs Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Y-mAbs Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Y-mAbs Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Y-mAbs Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Y-mAbs Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-15.714	/	87.685
	=	-17.92 %

Y-mAbs Therapeutics's FCF Margin for the quarter that ended in Mar. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	-7.038	/	20.904
	=	-33.67 %

Y-mAbs Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Y-mAbs Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Y-mAbs Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-mAbs Therapeutics Inc (NAS:YMAB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

202 Carnegie Center, Suite 301, Princeton, NJ, USA, 08540

Website

https://www.ymabs.com

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Executives

Michael J Rossi	director, officer: President & CEO	230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Thomas Gad	director, officer: President and Chairman	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Torben Lund-hansen	officer: Sr. VP and Head of Tech Op	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Joris Wilms	officer: Sr. VP and COO	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Bo Kruse	director, officer: EVP, CFO, Secy & Treas.	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Vignesh Rajah	officer: SVP and CMO	HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950
Susan Laura Smith	officer: Senior Vice President, CCO	5 OVERLOOK CT, LAMBERTVILLE NJ 08530
Johan Wedell-wedellsborg	director, 10 percent owner	RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
Biotech Aps Wg	10 percent owner	RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960
David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Juan Moller San Pedro Claus	director, officer: Chief Executive Officer	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Mahiuddin Ahmed	officer: Sr. VP and CSO	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169
Philip Karl Herman	officer: Sr. VP and CCO	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169